Bangladesh M&A · January–March 2026.

Q1 2026 closed with five disclosed transactions worth approximately USD 41 million in aggregate¹ — the highest first-quarter count on record and the first quarter where pharma roll-up activity matched logistics-and-commerce by deal count rather than value⁹. Both the count and the value sit meaningfully above the trailing eight-quarter mean, with deal count reaching its highest level in any quarter since the tracker began.

Three structural factors drove the strong opener: a stabilised taka–dollar band across January and February¹¹, the November-2025 Bangladesh Bank inward-FDI fast-track meeting its sixty-day target on three of three cross-border approvals¹², and the BSEC February interpretive note clarifying SME exemption thresholds for private-company share transfers¹³. Underneath the headline number, the composition of activity continued the pattern set in late 2025: listed pharma absorbing formulations capacity, acqui-hire mechanics dominating tech, and an early signal of mid-market F&B consolidation finally clearing a first transaction⁷.

The report below covers the chart of quarterly volume and value (Fig. 01), the Q1 sector breakdown by count and BDT aggregate (Tbl. 01), three regulatory readouts from BSEC, Bangladesh Bank and RJSC, four patterns the desk has been tracking, and a complete methodology and source list. All figures are directional and subject to revision.

Four shifts the desk has been tracking.

Listed pharma is in roll-up mode. Three of the past five quarters have featured at least one listed-pharma acquisition of a privately-held formulations manufacturer⁹. The pattern is structural rather than opportunistic: DSE-listed acquirers are absorbing sub-scale capacity faster than the next generation of family owners is willing to operate it. Q1 2026 saw two such transactions, one closed and one in late-stage regulatory clearance with DGDA. We expect this to continue through 2026 with at least four to six more transactions in the pipeline based on advisor conversations.

Acqui-hire mechanics dominate tech. Sub-USD-5M tech transactions in Q1 were almost universally structured as talent-priced acquisitions — sunset products, retention-heavy compensation, and earnouts tied to integration milestones rather than standalone product performance⁶. Two of the five Q1 transactions fall into this bucket, including an agritech analytics team acquired for cold-chain capability rather than for the underlying product. Standalone SaaS exits at meaningful revenue multiples remained rare; the desk continues to track only one Bangladeshi SaaS transaction in the past eighteen months that cleared at above 3x ARR.

Mid-market F&B consolidation is finally moving. After two years of stalled negotiations, mid-market restaurant-chain consolidation closed its first material transaction in Q1 — an eleven-outlet Dhaka chain merging with a five-outlet Chittagong operator in a share-swap structure⁷. Several similar conversations are reportedly active across both ends of the corridor; at least two further announcements are expected over the next two quarters. The structural driver is straightforward: scaling from ten to thirty outlets requires either external growth capital or a merger, and the local debt market is materially more accommodating to the post-merger entity than the standalone.

Foreign acquirers are back at the negotiating table. Cross-border buyer participation in Q1 reached its highest level since H1 2024¹², helped by the Bangladesh Bank fast-track and the more stable taka–dollar setup¹¹. The discount foreign buyers were demanding for FX risk has narrowed materially. Three of the five Q1 transactions involved foreign capital and all three cleared FED approval inside the sixty-day target — the first quarter on record where every cross-border deal cleared inside the target window.

Taken together, these four patterns suggest a market shifting from sporadic activity toward a recognisable operating cadence. The reporting will continue to lag the underlying activity by a wide margin — for every announced deal we count, advisor conversations imply two to three private closes at the SME tier¹⁵ — but the trend is no longer ambiguous.

Q2 setup.

Three structural factors point to Q2 2026 sustaining or modestly exceeding the Q1 deal cadence. First, the listed-pharma roll-up pipeline appears, from advisor conversations, to have at least three deals in late-stage diligence. Second, the Bangladesh Bank fast-track facility is now stable enough to be priced into cross-border deal timelines without an uncertainty discount. Third, the RJSC Form 117 digitisation has begun to compress execution timelines in a way that visibly improves close-rates on signed deals.

Our base case calls for six to eight announced transactions in Q2 2026 with aggregate value in the USD 35–55M range — a result that, if delivered, would put the market on track for an annual count comfortably above the 2025 trailing twelve-month figure and represent the most active first half of any year on record for Bangladesh M&A. The principal downside risks remain external: a renewed taka weakness, a sharp move in the policy rate either direction, or a regulatory shift that reverses the SME share-transfer exemption would each materially reset the picture. None appear imminent.